Cantor Fitzgerald analyst Steven Halper lowered his price target for NextGen Healthcare to $23 from $26 following the company’s “mixed” Q2 results. Revenue was slightly below the analyst’s estimate but adjusted earnings came in above. While the lowered fiscal 2019 outlook is disappointing, the shares offer an attractive risk/return profile, Halper tells investors in a post-earnings research note. He believes NextGen’s turnaround continues.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.